Related Experiment Videos
Choice of therapy in chronic ischemic heart disease
Insights
Ambulatory monitoring helps differentiate heart disease causes. This guides treatment, distinguishing between increased oxygen demand responsive to beta blockers and coronary spasm treated with calcium antagonists for better outcomes.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Chronic ischemic heart disease treatment choice hinges on mechanism identification.
- Ambulatory monitoring aids in differentiating causes of angina.
- Patient history alone can be misleading in diagnosing angina.
Purpose of the Study:
- To highlight the role of ambulatory monitoring in guiding therapy for chronic ischemic heart disease.
- To differentiate treatment strategies based on underlying mechanisms like increased myocardial oxygen demand versus coronary spasm.
- To emphasize the significance of silent myocardial ischemia.
Main Methods:
- Utilizing ambulatory monitoring to assess myocardial oxygen demand and identify coronary spasm.
- Analyzing nocturnal angina patterns to determine underlying causes.
- Considering factors like smoking and silent ischemia in therapeutic decisions.
Main Results:
- Ambulatory monitoring identifies patients benefiting from beta blockers (increased demand) versus calcium antagonists (coronary spasm).
- Nocturnal angina often stems from increased myocardial oxygen demand, managed by heart rate control with specific beta blockers.
- Silent myocardial ischemia episodes carry hemodynamic significance comparable to painful episodes.
Conclusions:
- Tailoring therapy based on ambulatory monitoring findings improves chronic ischemic heart disease management.
- Beta blockers without intrinsic sympathomimetic activity are recommended for nocturnal angina due to increased demand.
- Further research is needed on the therapeutic and prognostic implications of silent myocardial ischemia.
Abstract:
The choice of therapy in chronic ischemic heart disease depends on identifying the underlying mechanism. Ambulatory monitoring provides a means of identifying those patients in whom increased myocardial oxygen demand is the most important mechanism and who will respond to a beta blocker. In contrast, those patients with coronary spasm are best treated with a calcium antagonist. The history of angina pectoris and the time of onset may, in itself, be misleading. Detailed ambulatory monitoring studies show that nocturnal angina is frequently due to increased myocardial oxygen demand and in such circumstances should be treated by careful control of the heart rate using a beta blocker without intrinsic sympathomimetic activity. Other factors that will influence the choice of medical therapy must be considered. Smoking is particularly important because it not only acts detrimentally in terms of increased myocardial oxygen demand, but may also interfere with the metabolism of those antianginal agents that are metabolized in the liver. The importance of silent myocardial ischemia has been emphasized recently, and studies using ambulatory pulmonary artery monitoring have shown that silent ischemic episodes have the same significance in terms of hemodynamic effects as painful ischemic episodes. The therapeutic and prognostic implications of these findings need to be explored.